Next-Generation Sequencing in Lung Cancer Patients: A Comparative Approach in NSCLC and SCLC Mutational Landscapes

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.

Autoři	POP-BICA Cecilia CIOCAN Cristina Alexandra BRAICU Cornelia HARANGUS Antonia SIMON Marioara NUTU Andreea POP Laura Ancuta SLABÝ Ondřej ATANASOV Atanas G PIRLOG Radu NADIM Al Hajjar BERINDAN-NEAGOE Ioana
Rok publikování	2022
Druh	Článek v odborném periodiku
Časopis / Zdroj	Journal of Personalized Medicine
Fakulta / Pracoviště MU	Středoevropský technologický institut
Citace
www	https://www.mdpi.com/2075-4426/12/3/453
Doi	http://dx.doi.org/10.3390/jpm12030453
Klíčová slova	non-small-cell lung cancer; small-cell lung cancer; targeted sequencing; patients
Popis	Background: Lung cancer remains one of the most diagnosed malignancies, being the second most diagnosed cancer, while still being the leading cause of cancer-related deaths. Late diagnosis remains a problem, alongside the high mutational burden encountered in lung cancer. Methods: We assessed the genetic profile of cancer genes in lung cancer using The Cancer Genome Atlas (TCGA) datasets for mutations and validated the results in a separate cohort of 32 lung cancer patients using tumor tissue and whole blood samples for next-generation sequencing (NGS) experiments. Another separate cohort of 32 patients was analyzed to validate some of the molecular alterations depicted in the NGS experiment. Results: In the TCGA analysis, we identified the most commonly mutated genes in each lung cancer dataset, with differences among the three histotypes analyzed. NGS analysis revealed TP53, CSF1R, PIK3CA, FLT3, ERBB4, and KDR as being the genes most frequently mutated. We validated the c.1621A>C mutation in KIT. The correlation analysis indicated negative correlation between adenocarcinoma and altered PIK3CA (r = -0.50918; p = 0.0029). TCGA survival analysis indicated that NRAS and IDH2 (LUAD), STK11 and TP53 (LUSC), and T53 (SCLC) alterations are correlated with the survival of patients. Conclusions: The study revealed differences in the mutational landscape of lung cancer histotypes.